Vimarsana
Biggest News Aggregation in the World

Page 49 - Pharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Inc Today - Breaking & Trending Today

Hookipa Pharma Inc (HOOK) Shares Rise Despite Market Challenges - Vimarsana News

Hookipa Pharma Inc (HOOK) Shares Rise Despite Market Challenges

The stock of Hookipa Pharma Inc (NASDAQ: HOOK) has increased by 10.21 when compared to last closing price of 0.45. Despite this, the company has experienced a 18.69% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-02 that NEW YORK and VIENNA, Austria, Nov.

MEI Pharma, Inc. Announces Dividend of $1.75 (NASDAQ:MEIP) - Vimarsana News

MEI Pharma, Inc. Announces Dividend of $1.75 (NASDAQ:MEIP)

MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report) announced a dividend on Monday, November 6th, NASDAQ reports. Investors of record on Friday, November 17th will be given a dividend of 1.75 per share on Wednesday, December 6th. The ex-dividend date is Thursday, November 16th. MEI Pharma Stock Performance MEIP stock traded down $0.24 during trading […]

Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates - Vimarsana News

Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates

Advancements in Clinical Trials and AI Platform Highlighted Amid Financial Discipline

Source: yahoo.com
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights - Vimarsana News

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial expected to start in 2024 Published peer-reviewed preclinical data, in collaboration with Gilead Sciences, for HB-400 program in The Journal of Infectious Disease Recruitment ongoing for two Phase 1 clinical trials

Source: yahoo.com
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis - Vimarsana News

Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis

Preclinical data that supported initiation of the completed Phase 1a AP02 inhaled nintedanib study to be presented for the first time at the PFF Summit AP01…

Source: biztoc.com